Sorafenib and triptolide loaded cancer cell-platelet hybrid membrane-camouflaged liquid crystalline lipid nanoparticles for the treatment of hepatocellular carcinoma

Abstract In addition to early detection, early diagnosis, and early surgery, it is of great significance to use new strategies for the treatment of hepatocellular carcinoma (HCC). Studies showed that the combination of sorafenib (SFN) and triptolide (TPL) could reduce the clinical dose of SFN and ma...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zhe Li, Gang Yang, Lu Han, Rong Wang, Chunai Gong, Yongfang Yuan
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Sorafenib Triptolide Biomimetic nanoparticles Hepatocellular carcinoma Biotechnology TP248.13-248.65 Medical technology R855-855.5
Acceso en línea:	https://doaj.org/article/1d25b4879e14403eb8ab6ea156d3f244
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1d25b4879e14403eb8ab6ea156d3f244
record_format	dspace
spelling	oai:doaj.org-article:1d25b4879e14403eb8ab6ea156d3f2442021-11-14T12:29:24ZSorafenib and triptolide loaded cancer cell-platelet hybrid membrane-camouflaged liquid crystalline lipid nanoparticles for the treatment of hepatocellular carcinoma10.1186/s12951-021-01095-w1477-3155https://doaj.org/article/1d25b4879e14403eb8ab6ea156d3f2442021-11-01T00:00:00Zhttps://doi.org/10.1186/s12951-021-01095-whttps://doaj.org/toc/1477-3155Abstract In addition to early detection, early diagnosis, and early surgery, it is of great significance to use new strategies for the treatment of hepatocellular carcinoma (HCC). Studies showed that the combination of sorafenib (SFN) and triptolide (TPL) could reduce the clinical dose of SFN and maintain good anti-HCC effect. But the solubility of SFN and TPL in water is low and both drugs have certain toxicity. Therefore, we constructed a biomimetic nanosystem based on cancer cell-platelet (PLT) hybrid membrane camouflage to co-deliver SFN and TPL taking advantage of PLT membrane with long circulation functions and tumor cell membrane with homologous targeting. The biomimetic nanosystem, SFN and TPL loaded cancer cell-PLT hybrid membrane-camouflaged liquid crystalline lipid nanoparticles ((SFN + TPL)@CPLCNPs), could simultaneously load SFN and TPL at the molar ratio of SFN to TPL close to 10:1. (SFN + TPL)@CPLCNPs achieved long circulation function and tumor targeting at the same time, promoting tumor cell apoptosis, inhibiting tumor growth, and achieving a better "synergy and attenuation effect", which provided new ideas for the treatment of HCC. Graphical AbstractZhe LiGang YangLu HanRong WangChunai GongYongfang YuanBMCarticleSorafenibTriptolideBiomimetic nanoparticlesHepatocellular carcinomaBiotechnologyTP248.13-248.65Medical technologyR855-855.5ENJournal of Nanobiotechnology, Vol 19, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Sorafenib Triptolide Biomimetic nanoparticles Hepatocellular carcinoma Biotechnology TP248.13-248.65 Medical technology R855-855.5
spellingShingle	Sorafenib Triptolide Biomimetic nanoparticles Hepatocellular carcinoma Biotechnology TP248.13-248.65 Medical technology R855-855.5 Zhe Li Gang Yang Lu Han Rong Wang Chunai Gong Yongfang Yuan Sorafenib and triptolide loaded cancer cell-platelet hybrid membrane-camouflaged liquid crystalline lipid nanoparticles for the treatment of hepatocellular carcinoma
description	Abstract In addition to early detection, early diagnosis, and early surgery, it is of great significance to use new strategies for the treatment of hepatocellular carcinoma (HCC). Studies showed that the combination of sorafenib (SFN) and triptolide (TPL) could reduce the clinical dose of SFN and maintain good anti-HCC effect. But the solubility of SFN and TPL in water is low and both drugs have certain toxicity. Therefore, we constructed a biomimetic nanosystem based on cancer cell-platelet (PLT) hybrid membrane camouflage to co-deliver SFN and TPL taking advantage of PLT membrane with long circulation functions and tumor cell membrane with homologous targeting. The biomimetic nanosystem, SFN and TPL loaded cancer cell-PLT hybrid membrane-camouflaged liquid crystalline lipid nanoparticles ((SFN + TPL)@CPLCNPs), could simultaneously load SFN and TPL at the molar ratio of SFN to TPL close to 10:1. (SFN + TPL)@CPLCNPs achieved long circulation function and tumor targeting at the same time, promoting tumor cell apoptosis, inhibiting tumor growth, and achieving a better "synergy and attenuation effect", which provided new ideas for the treatment of HCC. Graphical Abstract
format	article
author	Zhe Li Gang Yang Lu Han Rong Wang Chunai Gong Yongfang Yuan
author_facet	Zhe Li Gang Yang Lu Han Rong Wang Chunai Gong Yongfang Yuan
author_sort	Zhe Li
title	Sorafenib and triptolide loaded cancer cell-platelet hybrid membrane-camouflaged liquid crystalline lipid nanoparticles for the treatment of hepatocellular carcinoma
title_short	Sorafenib and triptolide loaded cancer cell-platelet hybrid membrane-camouflaged liquid crystalline lipid nanoparticles for the treatment of hepatocellular carcinoma
title_full	Sorafenib and triptolide loaded cancer cell-platelet hybrid membrane-camouflaged liquid crystalline lipid nanoparticles for the treatment of hepatocellular carcinoma
title_fullStr	Sorafenib and triptolide loaded cancer cell-platelet hybrid membrane-camouflaged liquid crystalline lipid nanoparticles for the treatment of hepatocellular carcinoma
title_full_unstemmed	Sorafenib and triptolide loaded cancer cell-platelet hybrid membrane-camouflaged liquid crystalline lipid nanoparticles for the treatment of hepatocellular carcinoma
title_sort	sorafenib and triptolide loaded cancer cell-platelet hybrid membrane-camouflaged liquid crystalline lipid nanoparticles for the treatment of hepatocellular carcinoma
publisher	BMC
publishDate	2021
url	https://doaj.org/article/1d25b4879e14403eb8ab6ea156d3f244
work_keys_str_mv	AT zheli sorafenibandtriptolideloadedcancercellplatelethybridmembranecamouflagedliquidcrystallinelipidnanoparticlesforthetreatmentofhepatocellularcarcinoma AT gangyang sorafenibandtriptolideloadedcancercellplatelethybridmembranecamouflagedliquidcrystallinelipidnanoparticlesforthetreatmentofhepatocellularcarcinoma AT luhan sorafenibandtriptolideloadedcancercellplatelethybridmembranecamouflagedliquidcrystallinelipidnanoparticlesforthetreatmentofhepatocellularcarcinoma AT rongwang sorafenibandtriptolideloadedcancercellplatelethybridmembranecamouflagedliquidcrystallinelipidnanoparticlesforthetreatmentofhepatocellularcarcinoma AT chunaigong sorafenibandtriptolideloadedcancercellplatelethybridmembranecamouflagedliquidcrystallinelipidnanoparticlesforthetreatmentofhepatocellularcarcinoma AT yongfangyuan sorafenibandtriptolideloadedcancercellplatelethybridmembranecamouflagedliquidcrystallinelipidnanoparticlesforthetreatmentofhepatocellularcarcinoma
_version_	1718429152739065856

Sorafenib and triptolide loaded cancer cell-platelet hybrid membrane-camouflaged liquid crystalline lipid nanoparticles for the treatment of hepatocellular carcinoma

Ejemplares similares